1Rittling SR, Chambers AF. Role of osteopontin in tumour progression [J]. Br J Cancer, 2004; 90(10): 1877-1881.
2Uhm JH, Gladson CL, Rao JS. The role of integrins in the malignant phenotype of gliomas [J]. Front Biosci, 1999; 15 (4): 188-199.
3Furger KA, Allan AL, Wilson SM, et al. β3 integrin expression increases breast carcino ma cell responsiveness to the malignancy-enhancing effects of osteopontin [J]. Mol Cancer Res, 2003; 1(11): 810-819.
4Takahashi F, Takahashi K, Maeda K, et al. Osteopontin is induced by nitric oxide in RAW 264.7 cells [J]. IUBMB Life, 2000; 49(3): 217-221.
5Rooprai HK, Vanmeter T, Panou C, et al. The role of integrin receptors in aspects of glioma invasion in vitro [J]. Int J Dev Neurosci, 1999; 17(5-6): 613-623.
6Weber GF, Ashkar S. Molecular mechanisms of tumor dissemination in primary and metastatic brain cancers [J]. Brain Res Bull, 2000; 53(4): 421-424.
7Takano S, Tsuboi K, Tomono Y, et al. Tissue factor, osteopontin, αvβ3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression [J]. Br J Cancer, 2000; 82(12): 1967-1973.
8Iwamoto FM, Hormigo A. Unveiling YKL-40, from serum marker to target therapy in glioblastoma [J]. Front Oncol, 2014, 4: 90.
9Clement V, Dutoit V, Marino D, et O1. Limits of CD133 as a marker of glioma self-renewing cells [J]. Int J Cancer, 2009, 125(1): 244-248.
10Iwamoto FM, Hottinger AF, Karimi S, et al. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas [J]. Neuro Oncol, 20!1, 13(11): 1244-1251.
